Hanmi's BH3120 Immunotherapy Advances in Trials

Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical recently presented progress on BH3120, their innovative immunotherapy, at the Society for Immunotherapy of Cancer (SITC) conference in Houston, USA. BH3120, developed using Hanmi's "Pentambody" dual-antibody platform, targets PD-L1 on cancer cells and 4-1BB on immune cells, enhancing immune responses against tumors.

Preclinical studies showed significant anticancer efficacy and minimized side effects. Currently, a Phase 1 trial in South Korea and the U.S. demonstrates promising safety and tolerability in advanced solid tumor patients, advancing through dose escalation with no major toxicities reported.